Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
Evidence dashboardStudies since 2004Updated Jul 31, 2026

PasireotideClinical Trials.

A source-linked view of every Pasireotide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.

Total trials
75
Recruiting
5
Completed
50
Terminated
10
Results posted
35
Average enrollment
60
Countries
41
Highest phase
Phase 4

Largest indexed study

358 participants · NCT00600886 →

Developer / research origin

Novartis

Evidence summary

Activity is not efficacy.

Pasireotide appears in 75 indexed studies: 5 recruiting, 50 completed and 35 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Pasireotide is safe or effective.

Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.

Development history

Trial timeline.

Evidence timeline

2004—2025

200420042004200620082009200920092010201020102010201120112011201120112011

Velocity

Pasireotide studies by start year

Study start year · indexed snapshot

131073020042004: 4 trials2005: 0 trials2006: 2 trials2007: 1 trials20082008: 3 trials2009: 3 trials2010: 6 trials2011: 13 trials20122012: 9 trials2013: 7 trials2014: 3 trials2015: 5 trials20162016: 5 trials2017: 3 trials2018: 1 trials2019: 1 trials20202020: 2 trials2021: 0 trials2022: 0 trials2023: 1 trials20242024: 3 trials20252025: 3 trials

Development

Trials by phase

Early Phase 10
Phase 117
Phase 238
Phase 310
Phase 48

Current studies

Recruiting or active

Completed studies

Finished records

Stopped studies

Withdrawn or terminated

Showing 6 of 8 studies
Showing 6 of 50 studies
Showing 6 of 14 studies

Full study index

Search Pasireotide trials.

Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.

75 matching studies

Latest publications

Follow the paper trail.

PMID 38851203 ↗Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, Garcia-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.Linked from NCT03972488PMID 40473457 ↗Holzgreve A, Unterrainer LM, Tiling M, Mansour N, Spitzweg C, Brendel M, Ricke J, Unterrainer M, Kunz WG, Mehrens D. Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trial. J Nucl Med. 2025 Jul 1;66(7):1075-1081. doi: 10.2967/jnumed.124.269416.Linked from NCT03972488PMID 39570708 ↗Bahri N, Crook C, Daneng Li. Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment? Oncology (Williston Park). 2024 Nov 5;38(11):442-443. doi: 10.46883/2024.25921029.Linked from NCT03972488PMID 33973550 ↗Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol. 2021 Jul 1;33(4):378-385. doi: 10.1097/CCO.0000000000000740.Linked from NCT03972488PMID 35427770 ↗Beffara B, Hadj-Bouziane F, Hamed SB, Boehler CN, Chelazzi L, Santandrea E, Macaluso E. Dynamic causal interactions between occipital and parietal cortex explain how endogenous spatial attention and stimulus-driven salience jointly shape the distribution of processing priorities in 2D visual space. Neuroimage. 2022 Jul 15;255:119206. doi: 10.1016/j.neuroimage.2022.119206. Epub 2022 Apr 12.Linked from NCT02713776PMID 40934647 ↗Heilig CE, Heining C, Gnutzmann E, Roldan S, Heiligenthal L, Sparber-Sauer M, Hahn D, Dirksen U, Hamacher R, Florcken A, Thorwarth A, Deinzer CKW, Gaidzik VI, Pfaff E, Hubschmann D, Arndt K, Pfister SM, Glimm H, Frohling S, Schlenk RF. Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trial. Cancer Treat Res Commun. 2025;45:100986. doi: 10.1016/j.ctarc.2025.100986. Epub 2025 Sep 3.Linked from NCT06456359PMID 31440946 ↗Manetti L, Deutschbein T, Schopohl J, Yuen KCJ, Roughton M, Kriemler-Krahn U, Tauchmanova L, Maamari R, Giordano C. Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing's disease: interim results from a long-term real-world evidence study. Pituitary. 2019 Oct;22(5):542-551. doi: 10.1007/s11102-019-00984-6.Linked from NCT02310269PMID 25376618 ↗Cives M, Kunz PL, Morse B, Coppola D, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015 Feb;22(1):1-9. doi: 10.1530/ERC-14-0360. Epub 2014 Nov 6.Linked from NCT01253161

Related pages

Keep researching Pasireotide.

Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.

DatabasePasireotide database page →Research guideRead the Pasireotide guide →Lab reportsSearch the COA ledger →Source registrySearch ClinicalTrials.gov ↗